BPM31510 + docetaxel

BPM31510 + docetaxel is a combination therapy under investigation for cancer treatment. **BPM31510** is a novel lipid-based nanodispersion that delivers supraphysiological levels of **ubidecarenone** (oxidized coenzyme Q10, or CoQ10) to tumor mitochondria. This agent is designed to exploit cancer cell metabolism by increasing mitochondrial oxidative phosphorylation (OxPhos), generating reactive oxygen species (ROS), and triggering selective apoptosis in cancer cells while sparing normal cells. **Docetaxel** is a microtubule inhibitor used widely in the treatment of various solid tumors, acting by stabilizing microtubules and inhibiting cell division. The combination of BPM31510 and docetaxel is based on the rationale that modulating tumor redox and energetics with BPM31510 may sensitize tumors to chemotherapeutic agents like docetaxel, enhancing anti-tumor efficacy. BPM31510 is developed by BPGbio (formerly BERG), and has primarily been studied in combination with chemotherapy in solid tumors such as pancreatic cancer and glioblastoma, although published trials to date emphasize use with gemcitabine or temozolomide rather than docetaxel specifically[1][8].